European Commission Opens Antitrust Investigation Against Teva Over Multiple-Sclerosis Drug
By Cecilia Butini
The European Commission said Thursday that it has opened a
formal antitrust investigation into Israel-based pharmaceutical
company Teva Pharmaceutical Industries Ltd. to assess whether it
behaved in an anti-competitive manner with regards to its
multiple-sclerosis drug Copaxone.
The investigation aims to determine whether Teva illegally
delayed the market entry and uptake of medicines that compete with
its own, the Commission said.
It will also examine whether the company has put together a
communication campaign with the goal of hindering the use of
competing products with the same active principle, it said.
Teva's alleged behavior may amount to an abuse of dominant
position if proven, the Commission said.
Write to Cecilia Butini at email@example.com
(END) Dow Jones Newswires
March 04, 2021 06:04 ET (11:04 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.